PresseBox
Press release BoxID: 314683 (QIAGEN N.V.)
  • QIAGEN N.V.
  • Hulsterweg 82
  • 5912 Venlo
  • http://www.qiagen.com
  • Contact person
  • Solveigh Karola Mähler
  • +49 (2103) 29-11710

QIAGEN Acquires ESE GmbH

Applications of newly added molecular detection technology include Point-of-Need testing in Molecular Diagnostics and Applied Testing

(PresseBox) (VENLO, The Netherlands , ) QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that it has acquired ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices. ESE is based in Stockach, Germany. The transaction is valued at up to US$19 million in cash.

ESE has pioneered the development and manufacturing of optical measurement systems for medical and industrial applications. The systems utilize unique, highperformance and awardwinning fluorescence detection technologies integrated into compact modules. ESE's solutions are considered as an emerging standard for the detection of fluorescent signals in a wide range of molecular testing applications, most notably in nucleic acidbased pointofneed testing. In addition to portable solutions for pointofneed testing, these miniaturized, lowcost fluorescence detection modules can be integrated in laboratory instruments as well.

The systems' "ultrafast time to result" and high portability open new opportunities in healthcare and applied testing (e.g. veterinary, food, environmental, biodefense testing), enabling lowthroughput molecular testing in practices, emergency rooms, remote field areas, and other settings where a laboratory infrastructure is not accessible and fast turnaround is required. ESE's fluorescence detection systems can be battery operated, process up to eight samples at a time and even permit testing of samples for several parameters in a single run (multiplex testing). As the proprietary technology allows for the detection modules to be manufactured at very low cost, the complete solutions can sell for less than US$2,000 per unit - significantly below the price of other comparable testing systems.

QIAGEN has demonstrated that ESE's fluorescence detection systems can be used to measure signals generated by the Company's existing testing technologies, including the HDA and tHDA isothermal assay systems, which QIAGEN has licensed from BioHelix in 2008. These isothermal assay technologies are an integral part of QIAGEN's next generation screening platform QIAensemble. Therefore, assay development for the fluorescence detection systems can benefit from ongoing research activities for the QIAensemble platform.

QIAGEN has verified the ability of ESE's systems to run HDAbased assays for several pathogens including Salmonella and E.coli bacteria as well as Influenza viruses. Analysis can be performed directly on samples (i.e., from crude blood) or following an upfront sample preparation step integrated into the devices using QIAGEN's proven sample technologies. Depending on the target, such assays can generate results in between 5 and 15 minutes. This represents a key breakthrough allowing the platform to meet the most important requirement in pointofneed testing: ultrafast time to result.

The transaction contributes to QIAGEN's strategy of expanding its technology leadership and of driving the dissemination of molecular sample and assay technologies into everyday life. It not only adds a novel detection platform to QIAGEN's portfolio of assay technologies, but also creates options for pointofneed test solutions in select markets. QIAGEN plans to develop and offer such solutions for a broad range of molecular diagnostic segments in Europe, Latin America and Asia. In the United States, QIAGEN intends to focus on select application fields such as acute care (emergency rooms, mobile testing) and critical care areas where rapid turnaround and/or portable solutions are required. These segments generally do not overlap with QIAGEN's current markets in the United States in terms of customers and assay menu. QIAGEN expects its first submissions for regulatory approval of corresponding assays to take place following the launch of clinical systems after 2011. In the developing world, QIAGEN sees a significant opportunity for the technology to expand its offering in infectious disease testing with pointofneed options. Together with PATH and the Bill & Melinda Gates Foundation, QIAGEN has already developed a version of its HPV test for public health programs in lowresource & developing countries that can be performed without electricity or running water and offers detection results within 2.5 hours.

Additionally, QIAGEN believes that there are several areas in applied testing which offer significant potential for pointofneed testing solutions. These include animal, food and environmental safety testing, where portability and the ability to be placed in diverse locations are key requirements perfectly addressed by the platform.

QIAGEN will establish ESE's development and manufacturing site in Stockach as a Center of Excellence in Detection Development and intends to retain and expand the employee base.

QIAGEN anticipates the onetime charges in connection with this acquisition not to exceed US$500,000 in 2010. The transaction is expected to contribute approximately US$6 million in sales in 2010. On an adjusted basis excluding onetime charges, integration and restructuring costs, and amortization of acquisition related intangible assets, the acquisition is expected to be neutral to EPS in 2010.